Matthew Henn

Company: Seres Therapeutics

Job title: Executive VP & CSO

Seminars:

Developing Bacterial Consortia Therapeutics for Infectious and Inflammatory Disease Targets 10:45 am

• Providing an update on Seres’ clinical and pre-clinical pipeline • Discussing candidates including SER-109, which in a Phase 3 Clinical Trial led to a statistically significant reduction in C.difficile recurrenceRead more

day: Day One